Business

#Business #Chemistry #Combinatorial chemistry #Drug development #Drug discovery #Enabling technologies #Lead discovery #Organic chemistry #RNA

SCAVENGER strategies in organic synthesis – Part Two

SCAVENGER strategies in organic synthesis - Part Two By Professor Peter Wipf and Dr Claire M. Coleman Part 1 of this article discussed the fundamental principles of the use of scavenging techniques in combinatorial and organic synthesis. Part one of scavenger strategies is linked here. In this article, more recent… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell culture #Cellular assays #Chemical engineering #Chemistry #Combinatorial chemistry #Drug development #Drug discovery #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Protein chemistry / Proteomics #RNA #Screening #System biology #Systems biology

Making the Most of Drug Discovery Data

Making the Most of Drug Discovery Data By Dr Nick Davies and Dr Tim Peakman Discovery scientists in most pharmaceutical companies are struggling with incompatible legacy systems, a growing volume of data and the imminent advent of a product model that will demand much more of them. Data-driven drug discovery… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Molecular medicine #PCR #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Toxicology

Gene Expression: Analysis and Drug R&D

Gene Expression: Analysis and Drug R&D By Dr Ralph Sinibaldi It is clear that gene expression profiling systems have a role to play in many facets of drug discovery and development, but several questions remain. We take a look at the use of DNA microarray for gene expression or expression… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #High Content Screening #Lead discovery #Protein chemistry / Proteomics #Sequencing #Therapeutics

Drug Discovery Spending – A Year In Review

Drug Discovery Spending - A Year In Review By Isaac Meek Drug In 2003, the research products market reported revenues of $23 billion, with a 7.5% growth rate over 2002. Although there are many consumers in this market, by far the greatest are drug discovery research groups. In recent history,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Oncology #PCR #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Target validation #Therapeutics #Toxicology

Using RNAi to identify and validate novel drug targets: targeting human kinases with an siRNA library

Using RNAi to identify and validate novel drug targets: targeting human kinases with an siRNA library By Andrea Kroenke, Anne Grabner, Dr Michael Hannus, Dr Christoph Sachse, Dr David Dorris and Dr Christophe Echeverri Libraries of siRNAs directed against predefined subsets of genes now offer the capacity to greatly accelerate… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Pathology #Pharmacogenomics #Pharmacology #Preclinical #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

Role of image informatics in accelerating drug discovery and development

Role of image informatics in accelerating drug discovery and development By Robert Dunkle There is a new category of informatics that is proving itself essential to the acceleration of drug discovery and development. Image informatics is the systematic use of image data as a means to help interpret experiments and… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #PCR #Pharmacology #RNA #Screening #Stem cells #System biology #Systems biology

New Flash Imagers: Facilitating higher throughput functional GPCR assays

New Flash Imagers: Facilitating higher throughput functional GPCR assays By Dr John Comley The recent availability of tailored automation solutions that combine liquid handling at the reading position with the latest innovations in low light imaging technology are providing screeners with new tools for the measurement of high throughput flash… Read More

#Archive

#ADME / Tox #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Flow Cytometry #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Medicinal chemistry #PCR #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Accommodating cells in HTS

Accommodating cells in HTS By Sandra Fox High Throughput Screening has become an important and integrated part of drug discovery at most pharmaceutical and many biotechnology companies worldwide, and is now entrenched in the drug discovery process. To produce high quality leads, centralised HTS laboratories are expanding their overall role… Read More

#Archive

#Biologics / Biotechnology #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #Lead discovery #Molecular medicine #Oncology #Preclinical #Regulatory #Sequencing #System biology #Systems biology #Theranostics #Therapeutics

Fewer drugs approved, more money spent – Where’s the beef?

Fewer drugs approved, more money spent - Where's the beef? By G. Steven Burrill Three years ago, when biotech was at its Wall Street heights, personalised medicine and its promise were on everyone's lips. Billions of dollars were being put to work to make targeted medicine a reality... and genomics… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Business #High Content Screening #RNA #Sequencing

Global Dealmaking (part 2) – The Negotiation

By Dr Paul Charlton To negotiate the optimum terms and conditions for deals which ensure a truly 'wise agreement', one that is mutually beneficial, realistically implementable, profitable and can withstand the inevitable knocks and trials that present themselves at usually the most inconvenient of moments should be the goal of… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cell culture #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #Toxicology

Automating cell culture to optimise cell line generation and selection

By Tim Ward Cell culture is and has historically been an essential component of the drug discovery toolbox. Cell culture provides the proteins, membrane preparations and other raw materials required for biological research. In recent years, with the emergence of high-throughput screening technology and binding and live, cell-based functional assays,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Business #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Organic chemistry #Protein chemistry / Proteomics #RNA #Screening #Sequencing #System biology #Systems biology

Recent advances in mass spectrometry for drug discovery and development

Recent advances in mass spectrometry for drug discovery and development By Dr Nelson Cooke Of the numerous types of analytical techniques used in drug discovery and development, mass spectrometry (MS) has become one of the most powerful tools for the analyses of a wide range of chemical and biological entities. Read More

#Archive

#Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug targets #Gene therapy #Genetics / genomes #Oncology #Pathology #Preclinical #RNA #Stem cells #System biology #Systems biology #Toxicology

DNA repair inhibition to treat cancer and other serious illnesses

DNA repair inhibition to treat cancer and other serious illnesses By Professor Stephen P. Jackson and Cheryl L. Bishop The stability of an organism's genome is essential for healthy functioning and survival. The information content and integrity of the genome are so important that a range of maintenance and repair… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Flow Cytometry #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Mass spectrometry / NMR #Molecular medicine #Oncology #Pathology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Protein BIOMARKER Strategies

By Dr Steven Bodovitz and Dr Scott D. Patterson The potential for parallel protein-based analyses to define a new era in diagnostics and drug development is generating considerable excitement in the field of proteomics. However, the discovery of differentially expressed proteins that correlate with a disease state or a drug… Read More

#Archive

#Academic #Business #High Content Screening #RNA

Global Dealmaking (part 1) – The Pitch

Global Dealmaking (part 1) - The Pitch By Dr Paul Charlton The age-old adage that your product is only as good as the person selling it still holds true in today's highly competitive pharmaceutical environment. Yet basic presentation skills are, in many cases, somewhat lacking. This article, the first of… Read More

#Archive

#AI / data analytics / healthtech / informatics #Animal models #Biomarkers #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Lead discovery #Orphan drugs #Regulatory #RNA #Screening

Biotechnology-based Orphan Drugs – Achievements and challenges

Biotechnology-based Orphan Drugs - Achievements and challenges By Dr Erik Tambuyzer For many patients suffering from rare diseases, there are simply no medicines available to treat their condition. With an estimated 20-30 million such patients in Europe alone, rare diseases collectively represent a significant unmet medical need. Individual disease groups,… Read More

#Archive